MRD assessments are probably 1 of the most powerful predictors that we have to see how well a treatment has worked, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
MRD assessments are probably 1 of the most powerful predictors that we have to see how well a treatment has worked, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Transcript
How accurate is MRD assessment at judging how deep remission is or how well a treatment worked?
So, it's actually very accurate. It's probably 1 of the most powerful predictors that we have to see how well a treatment has worked. In fact, most patients that do not achieve a complete remission will be minimal residual disease positive so that just tells you how good that is. There could be some instances, which are not many, where a patient could have what we call extramedullary disease—it’s a patient with multiple myeloma [who] comes in and has some mass or something somewhere, for example, in the ribs. It's not uncommon to have lesions in the bones that maybe have a little bit of a mass and then you treat the patient, and you do your MRD assessment in the bone marrow, which is basically just taking a little bit of blood from the bone marrow, maybe like a couple of millimeters or something like that.
Then you test that and that's negative, but then you do a PET CT or you do an MRI and you still see that there is something left in terms of where that rib lesion had been. So, in that situation, the patient obviously is not yet in remission—I mean, there's myeloma left, and you can treat that and keep checking the MRD, but sometimes there are some situations where MRD may tell you that it's negative, but there may be some residual disease; but these are not most of the situations in myeloma. So this is why again, for the response criteria, there's an imaging and MRD negativity. So, you can also do some imaging like whole body imaging, whole body PET CT is useful in these circumstances, as would be MRI.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More